search
Back to results

A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
ITCA 650
ITCA placebo
Sponsored by
Intarcia Therapeutics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • HBA1c > 6.5%
  • History of coronary, cerebrovascular or peripheral artery disease

Exclusion Criteria:

  • history of pancreatitis

Sites / Locations

  • Study Site
  • Intarcia Therapeutics, Inc
  • Study Site
  • Study Site
  • Study SIte
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

ITCA 650 60 mcg/day

ITCA placebo

Arm Description

ITCA 650 is exenatide in DUROS

Outcomes

Primary Outcome Measures

time to first occurrence of any event included in the MACE cardiovascular composite endpoint (CV death, non fatal MI, non fatal stroke, or hospitalization for unstable angina),

Secondary Outcome Measures

Full Information

First Posted
October 18, 2011
Last Updated
January 26, 2017
Sponsor
Intarcia Therapeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT01455896
Brief Title
A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650
Official Title
A Randomized, Multi-Center Study to Evaluate Cardiovascular Outcomes With ITCA 650 in Patients Treated With Standard of Care for Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
March 2013 (Actual)
Primary Completion Date
March 2016 (Actual)
Study Completion Date
March 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Intarcia Therapeutics

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Phase 3 study to Evaluate cardiovascular outcomes in patients with type 2 diabetes treated with ITCA 650.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
4156 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ITCA 650 60 mcg/day
Arm Type
Experimental
Arm Description
ITCA 650 is exenatide in DUROS
Arm Title
ITCA placebo
Arm Type
Other
Intervention Type
Drug
Intervention Name(s)
ITCA 650
Intervention Description
ITCA 650
Intervention Type
Other
Intervention Name(s)
ITCA placebo
Intervention Description
ITCA placebo
Primary Outcome Measure Information:
Title
time to first occurrence of any event included in the MACE cardiovascular composite endpoint (CV death, non fatal MI, non fatal stroke, or hospitalization for unstable angina),
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: HBA1c > 6.5% History of coronary, cerebrovascular or peripheral artery disease Exclusion Criteria: history of pancreatitis
Facility Information:
Facility Name
Study Site
City
Chandler
State/Province
Arizona
ZIP/Postal Code
85224
Country
United States
Facility Name
Intarcia Therapeutics, Inc
City
Hayward
State/Province
California
ZIP/Postal Code
94545
Country
United States
Facility Name
Study Site
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Facility Name
Study Site
City
Port Hueneme
State/Province
California
ZIP/Postal Code
93041
Country
United States
Facility Name
Study SIte
City
San Diego
State/Province
California
ZIP/Postal Code
92114
Country
United States
Facility Name
Study Site
City
Bradenton
State/Province
Florida
ZIP/Postal Code
34208
Country
United States
Facility Name
Study Site
City
New Port Richey
State/Province
Florida
ZIP/Postal Code
34652
Country
United States
Facility Name
Study Site
City
Palm Harbor
State/Province
Florida
ZIP/Postal Code
34684
Country
United States
Facility Name
Study Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60634
Country
United States
Facility Name
Study Site
City
Avon
State/Province
Indiana
ZIP/Postal Code
46123
Country
United States
Facility Name
Study Site
City
Evansville
State/Province
Indiana
ZIP/Postal Code
47714
Country
United States
Facility Name
Study Site
City
Franklin
State/Province
Indiana
ZIP/Postal Code
46131
Country
United States
Facility Name
Study Site
City
Greenfield
State/Province
Indiana
ZIP/Postal Code
46140
Country
United States
Facility Name
Study Site
City
Muncie
State/Province
Indiana
ZIP/Postal Code
47304
Country
United States
Facility Name
Study Site
City
Newton
State/Province
Kansas
ZIP/Postal Code
67114
Country
United States
Facility Name
Study Site
City
Wichita
State/Province
Kansas
ZIP/Postal Code
67205
Country
United States
Facility Name
Study Site
City
Wichita
State/Province
Kansas
ZIP/Postal Code
67207
Country
United States
Facility Name
Study Site
City
Metaire
State/Province
Louisiana
ZIP/Postal Code
70006
Country
United States
Facility Name
Study Site
City
Rochester
State/Province
Michigan
ZIP/Postal Code
48307
Country
United States
Facility Name
Study Site
City
St Louis
State/Province
Missouri
ZIP/Postal Code
63141
Country
United States
Facility Name
Study Site
City
Billings
State/Province
Montana
ZIP/Postal Code
59101
Country
United States
Facility Name
Study Site
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89128
Country
United States
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89148
Country
United States
Facility Name
Study Site
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
Facility Name
Study Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45236
Country
United States
Facility Name
Study Site
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43213
Country
United States
Facility Name
Study Site
City
Franklin
State/Province
Ohio
ZIP/Postal Code
45005
Country
United States
Facility Name
Study Site
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15236
Country
United States
Facility Name
Study Site
City
Uniontown
State/Province
Pennsylvania
ZIP/Postal Code
15401
Country
United States
Facility Name
Study Site
City
Greer
State/Province
South Carolina
ZIP/Postal Code
29651
Country
United States
Facility Name
Study Site
City
Austin
State/Province
Texas
ZIP/Postal Code
78745
Country
United States
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Facility Name
Study Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
Facility Name
Study Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
City
Plovdiv
ZIP/Postal Code
4002
Country
Bulgaria
City
Hvidovre
ZIP/Postal Code
2650
Country
Denmark
City
Oulu
ZIP/Postal Code
90100
Country
Finland
City
Bad Lauterberg im Harz
State/Province
Niedersachsen
ZIP/Postal Code
37431
Country
Germany
City
Sopot
ZIP/Postal Code
81-717
Country
Poland
City
Martin
ZIP/Postal Code
03659
Country
Slovakia
City
Johannesburg
State/Province
Gauteng
ZIP/Postal Code
2193
Country
South Africa
City
Istanbul
ZIP/Postal Code
34098
Country
Turkey

12. IPD Sharing Statement

Citations:
PubMed Identifier
34873344
Citation
Ruff CT, Baron M, Im K, O'Donoghue ML, Fiedorek FT, Sabatine MS. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nat Med. 2022 Jan;28(1):89-95. doi: 10.1038/s41591-021-01584-3. Epub 2021 Dec 6.
Results Reference
derived
PubMed Identifier
29693361
Citation
Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population. Am J Manag Care. 2018 Apr;24(8 Suppl):S146-S155.
Results Reference
derived

Learn more about this trial

A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

We'll reach out to this number within 24 hrs